Advertisement

Experimental Basis of New Therapeutic Approaches to Septic Shock

  • J. Cohen
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 16)

Abstract

In 1982, the distinguished scientist, David Tyrrell, wrote a monograph entitled “ The Abolition of Infection: Hope or Illusion?” [1]. In it, he drew attention to the fact that the long-expected demise of infection as a “problem” was evidently not going to happen. Issues such as the development of antibiotic resistance in common bacteria, and the contribution of the host to the pathophysiological disease would, he said, require new and innovative approaches to the treatment of infection. The need for these new strategies was particularly apparent in the case of septic shock. Mortality was “stuck”, rising to 75% or more in established cases [2], and it was clear that this high mortality was not due simply to the inadequacy of antibiotics.

Keywords

Tumor Necrosis Factor Septic Shock Bacterial Challenge Human Septic Shock Recombinant Human Tumor Necrosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tyrrell DA (1982) The abolition of infection. Hope or illusion? Nuffield Provincial Hospitals Trust, London, pp 1–66Google Scholar
  2. 2.
    Ispahani P, Pearson NJ, Greenwood D (1987) An analysis of community and hospital-acquired bacteraemia in a large teaching hospital in the United Kingdom. Q J Med 63:427–440PubMedGoogle Scholar
  3. 3.
    Flohe L, Giertz H (1987) Endotoxins, arachidonic acid, Superoxide formation. Rev Infect Dis 9:553–561CrossRefGoogle Scholar
  4. 4.
    Hinshaw LB, Peduzzi P, Young E, et al. (1987) Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317:659–665CrossRefGoogle Scholar
  5. 5.
    Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653–658PubMedCrossRefGoogle Scholar
  6. 6.
    McConnell JS, Appelmelk BJ, Cohen J (1990) Dissociation between Limulus neutralisation and in vivo protection in monoclonal antibodies directed against endotoxin core structures. Microb Pathogen 9:55–59CrossRefGoogle Scholar
  7. 7.
    Pollack M, Chia JK, Koles NL, Miller M, Guelde G (1989) Specificity and cross-reactivity of monoclonal antibodies reactive with the core and lipid A regions of bacterial lipopolysaccha-ride. J Infect Dis 159:168–188PubMedCrossRefGoogle Scholar
  8. 8.
    Heumann D; Baumgartner JD, Jacot-Guillarmod H, Glauser MP (1991) Antibodies to core li-popolysaccharide determinants: Absence of cross reactivity with heterologous lipopolysac-charides. J Infect Dis 163:762–768PubMedCrossRefGoogle Scholar
  9. 9.
    Appelmelk BJ, Verweij-Van Vught AM, Maaskant JJ, Schouten WF, Thijs LG, MacLaren DM ( 1986) Use of mucin and hemoglobin in experimental murine gram-negative bacteremia enhances the immunoprotective action of antibodies reactive with the lipopolysaccharide core region. Antonie van Leeuwenhoek 52:537–542PubMedCrossRefGoogle Scholar
  10. 10.
    Selye H, Tuchweber B, Bertok L (1966) Effect of lead acetate on the susceptibility of rats to bacterial endotoxins. J Bact 91:884–890PubMedGoogle Scholar
  11. 11.
    Lehmann V, Freudenberg MA, Galanos C (1987) Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. J Exp Med 165:657–663PubMedCrossRefGoogle Scholar
  12. 12.
    Overbeek BP, Veringa EM (1991) Role of antibodies and antibiotics in aerobic gram-negative septicemia: Possible synergism between antimicrobial treatment and immunotherapy. Rev Infect Dis 13:751–760PubMedCrossRefGoogle Scholar
  13. 13.
    Silva AT, Bayston KF, Cohen J (1990) Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor — alpha in experimental gram-negative shock. J Infect Dis 162:421–427PubMedCrossRefGoogle Scholar
  14. 14.
    Opal SM, Cross AS, Kelly NM, et al. (1990) Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseu-domonas aeruginosa. J Infect Dis 161:1148–1152PubMedCrossRefGoogle Scholar
  15. 15.
    Young LS, Gascon R, Alam S, Bermudez LE (1989) Monoclonal antibodies for treatment of gram-negative infections. Rev Infect Dis 11(Supp 7): 1564–1571CrossRefGoogle Scholar
  16. 16.
    Shenep JL (1986) Antibiotic-induced bacterial cell lysis: A therapeutic dilemma. Eur J Clin Microbiol 5:11–12PubMedCrossRefGoogle Scholar
  17. 17.
    Woods JP, Black JR, Barritt DS, Connell TD, Cannon JG (1987) Resistance to meningococ-cemia apparently conferred by anti-H.8 monoclonal antibody is due to contaminating endotoxin and not to specific immunoprotection. Infect Immun 55:1927–1928PubMedGoogle Scholar
  18. 18.
    Gearing AJ, Leung H, Bird CR, Thorpe R (1989) Presence of the inflammatory cytokines IL-1, TNF, and IL-6 in preparations of monoclonal antibodies. Hybridoma 8:361–367PubMedCrossRefGoogle Scholar
  19. 19.
    Beutler B, Milsark IW, Cerami A (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869–871PubMedCrossRefGoogle Scholar
  20. 20.
    Tracey KJ, Beutler B, Lowry SF, et al. (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234:470–474PubMedCrossRefGoogle Scholar
  21. 21.
    Rothstein JL, Schreiber H (1988) Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc Natl Acad Sci USA 85:607–611PubMedCrossRefGoogle Scholar
  22. 22.
    Kiener PA, Marek F, Rodgers G, Lin P-F, Warr G, Desiderio J (1988) Induction of tumor necrosis factor, IFN-gamma, and acute lethality in mice by toxic and non-toxic forms of Lipid A. J Immunol 141:870–874PubMedGoogle Scholar
  23. 23.
    Silva AT, Appelmelk BJ, Buurman WA, Bayston KF, Cohen J (1990) Monoclonal antibody to endotoxin core protects mice from Escherichia coli sepsis by a mechanism independent of tumor necrosis factor and interleukin-6. J Infect Dis 162:454–459PubMedCrossRefGoogle Scholar
  24. 24.
    Bagby GJ, Plessala KJ, Wilson LA, Thompson JJ, Nelson S (1991) Divergent efficacy of antibody to tumor necrosis factor alpha in intravascular and peritonitis models of sepsis. J Infect Dis 163:83–88PubMedCrossRefGoogle Scholar
  25. 25.
    Freudenberg MA, Galanos C (1991) Tumor necrosis factor alpha mediates lethal activity of killed gram-negative and gram-positive bacteria in D-galactosamine-treated mice. Infect Immun 59:2110–2115PubMedGoogle Scholar
  26. 26.
    Hinshaw LB, Emerson TE Jr, Taylor FB Jr, et al. (1992) Lethal Staphyococcus aureus-indu-ced shock in primates: Prevention of death with anti-TNF antibody. J Trauma (in press)Google Scholar
  27. 27.
    Wayte J, Silva AT, Cohen J (1991) Role of tumour necrosis factor (TNF) in experimental gram-positive sepsis. Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. (Abst) 789Google Scholar
  28. 28.
    Natanson C, Danner RL, Elin RJ, et al. (1989) Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. J Clin Invest 83:243–251PubMedCrossRefGoogle Scholar
  29. 29.
    Rokke O, Revhaug A, Osterud B, Giercksky ICE (1988) Increased plasma levels of endotoxin and corresponding changes in circulatory performance in a porcine sepsis model: The effect of antibiotic administration. Prog Clin Biol Res 272:247–262PubMedGoogle Scholar
  30. 30.
    Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA (1988) Interleukin-1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cy-clooxygenase inhibition. J Clin Invest 81:1162–1172PubMedCrossRefGoogle Scholar
  31. 31.
    Weinberg JR, Wright DJ, Guz A (1988) Interleukin-1 and tumor necrosis factor cause hypotension in the conscious rabbit. Clin Sci 75:251–255PubMedGoogle Scholar
  32. 32.
    Wakabayashi G, Gelfand JA, Jung WK, Connolly RJ, Burke JF, Dinarello CA (1991) Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shockk-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli. J Clin Invest 87:1925–1935PubMedCrossRefGoogle Scholar
  33. 33.
    Natanson C, Eichenholz PW, Danner RL, et al. (1989) Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 169:823–832PubMedCrossRefGoogle Scholar
  34. 34.
    Tracey KJ, Fong Y, Hesse DG, et al. (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662–664PubMedCrossRefGoogle Scholar
  35. 35.
    Minami A, Fujimoto K, Aozaki Y, Nakamura S (1988) Augmentation of host resistance to microbial infections by recombinant human interleukin-1 alpha. Infect Immun 56:3116–3120PubMedGoogle Scholar
  36. 36.
    Hinshaw LB, Tekamp-Olson P, Chang AC, et al. (1990) Survival of primates in LD 100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock 30:279–292PubMedGoogle Scholar
  37. 37.
    Exley AR, Buurman WA, Bodmer M, Cohen J (1989) Monoclonal antibody to recombinant human tumor necrosis factor in the prophylaxis and treatment of endotoxic shock in Cyno-molgus monkeys. Clin Sci 76:50pGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • J. Cohen

There are no affiliations available

Personalised recommendations